172 related articles for article (PubMed ID: 27882807)
1. JARID1/KDM5 demethylases as cancer targets?
Taylor-Papadimitriou J; Burchell J
Expert Opin Ther Targets; 2017 Jan; 21(1):5-7. PubMed ID: 27882807
[No Abstract] [Full Text] [Related]
2. The KDM5 family of histone demethylases as targets in oncology drug discovery.
Rasmussen PB; Staller P
Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
4. Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.
Labadie SS; Dragovich PS; Cummings RT; Deshmukh G; Gustafson A; Han N; Harmange JC; Kiefer JR; Li Y; Liang J; Liederer BM; Liu Y; Manieri W; Mao W; Murray L; Ortwine DF; Trojer P; VanderPorten E; Vinogradova M; Wen L
Bioorg Med Chem Lett; 2016 Sep; 26(18):4492-4496. PubMed ID: 27499454
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
[TBL] [Abstract][Full Text] [Related]
6. JARID1 Histone Demethylases: Emerging Targets in Cancer.
Harmeyer KM; Facompre ND; Herlyn M; Basu D
Trends Cancer; 2017 Oct; 3(10):713-725. PubMed ID: 28958389
[TBL] [Abstract][Full Text] [Related]
7. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen.
Sayegh J; Cao J; Zou MR; Morales A; Blair LP; Norcia M; Hoyer D; Tackett AJ; Merkel JS; Yan Q
J Biol Chem; 2013 Mar; 288(13):9408-17. PubMed ID: 23408432
[TBL] [Abstract][Full Text] [Related]
8. Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B.
Pippa S; Mannironi C; Licursi V; Bombardi L; Colotti G; Cundari E; Mollica A; Coluccia A; Naccarato V; La Regina G; Silvestri R; Negri R
Molecules; 2019 May; 24(9):. PubMed ID: 31060229
[No Abstract] [Full Text] [Related]
9. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.
Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Drewes G; Eagle R; Garton N; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Pemberton M; Rioja I; Seal GA; Shipley T; Singh O; Suckling CJ; Taylor J; Thomas P; Wilson DM; Lee K; Prinjha RK
J Med Chem; 2016 Feb; 59(4):1370-87. PubMed ID: 26771203
[TBL] [Abstract][Full Text] [Related]
10. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
Vinogradova M; Gehling VS; Gustafson A; Arora S; Tindell CA; Wilson C; Williamson KE; Guler GD; Gangurde P; Manieri W; Busby J; Flynn EM; Lan F; Kim HJ; Odate S; Cochran AG; Liu Y; Wongchenko M; Yang Y; Cheung TK; Maile TM; Lau T; Costa M; Hegde GV; Jackson E; Pitti R; Arnott D; Bailey C; Bellon S; Cummings RT; Albrecht BK; Harmange JC; Kiefer JR; Trojer P; Classon M
Nat Chem Biol; 2016 Jul; 12(7):531-8. PubMed ID: 27214401
[TBL] [Abstract][Full Text] [Related]
11. Structural analysis of human KDM5B guides histone demethylase inhibitor development.
Johansson C; Velupillai S; Tumber A; Szykowska A; Hookway ES; Nowak RP; Strain-Damerell C; Gileadi C; Philpott M; Burgess-Brown N; Wu N; Kopec J; Nuzzi A; Steuber H; Egner U; Badock V; Munro S; LaThangue NB; Westaway S; Brown J; Athanasou N; Prinjha R; Brennan PE; Oppermann U
Nat Chem Biol; 2016 Jul; 12(7):539-45. PubMed ID: 27214403
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation.
Liu K; Liu Y; Lau JL; Min J
Pharmacol Ther; 2015 Jul; 151():121-40. PubMed ID: 25857453
[TBL] [Abstract][Full Text] [Related]
13. RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3.
Christensen J; Agger K; Cloos PA; Pasini D; Rose S; Sennels L; Rappsilber J; Hansen KH; Salcini AE; Helin K
Cell; 2007 Mar; 128(6):1063-76. PubMed ID: 17320161
[TBL] [Abstract][Full Text] [Related]
14. 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.
Bavetsias V; Lanigan RM; Ruda GF; Atrash B; McLaughlin MG; Tumber A; Mok NY; Le Bihan YV; Dempster S; Boxall KJ; Jeganathan F; Hatch SB; Savitsky P; Velupillai S; Krojer T; England KS; Sejberg J; Thai C; Donovan A; Pal A; Scozzafava G; Bennett JM; Kawamura A; Johansson C; Szykowska A; Gileadi C; Burgess-Brown NA; von Delft F; Oppermann U; Walters Z; Shipley J; Raynaud FI; Westaway SM; Prinjha RK; Fedorov O; Burke R; Schofield CJ; Westwood IM; Bountra C; Müller S; van Montfort RL; Brennan PE; Blagg J
J Med Chem; 2016 Feb; 59(4):1388-409. PubMed ID: 26741168
[TBL] [Abstract][Full Text] [Related]
15. KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges.
Li CY; Wang W; Leung CH; Yang GJ; Chen J
Mol Cancer; 2024 May; 23(1):109. PubMed ID: 38769556
[TBL] [Abstract][Full Text] [Related]
16. Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.
Zheng YC; Chang J; Wang LC; Ren HM; Pang JR; Liu HM
Eur J Med Chem; 2019 Jan; 161():131-140. PubMed ID: 30343192
[TBL] [Abstract][Full Text] [Related]
17. A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2'-Deoxycytidine.
Leadem BR; Kagiampakis I; Wilson C; Cheung TK; Arnott D; Trojer P; Classon M; Easwaran H; Baylin SB
Cancer Res; 2018 Mar; 78(5):1127-1139. PubMed ID: 29282222
[TBL] [Abstract][Full Text] [Related]
18. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
Rotili D; Tomassi S; Conte M; Benedetti R; Tortorici M; Ciossani G; Valente S; Marrocco B; Labella D; Novellino E; Mattevi A; Altucci L; Tumber A; Yapp C; King ON; Hopkinson RJ; Kawamura A; Schofield CJ; Mai A
J Med Chem; 2014 Jan; 57(1):42-55. PubMed ID: 24325601
[TBL] [Abstract][Full Text] [Related]
19. Compounds and methods for inhibiting histone demethylases: a patent evaluation of US20160102096A1.
Thaler F; Mercurio C
Expert Opin Ther Pat; 2016 Dec; 26(12):1367-1370. PubMed ID: 27730846
[TBL] [Abstract][Full Text] [Related]
20. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases.
Luo X; Liu Y; Kubicek S; Myllyharju J; Tumber A; Ng S; Che KH; Podoll J; Heightman TD; Oppermann U; Schreiber SL; Wang X
J Am Chem Soc; 2011 Jun; 133(24):9451-6. PubMed ID: 21585201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
